Ervebo
What Ervebo is used for
Ervebo is indicated for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus. The use of Ervebo should be in accordance with official recommendations.
Approved use, as published by the European Medicines Agency.
What the labels mean
- PRIME: a priority medicine that the EMA supported early because it may meet an unmet need.
Key facts
- Brand
- Ervebo
- Active substance
- Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live)
- Disease area
- Hemorrhagic Fever, Ebola
- Medicine group
- Vaccines
- Marketing authorisation holder
- Merck Sharp & Dohme B.V.
- Authorised in the EU since
- 2019
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ervebo used for?
Ervebo is indicated for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus. The use of Ervebo should be in accordance with official recommendations.
What is the active substance in Ervebo?
Ervebo contains Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live).
Who makes Ervebo?
The EU marketing authorisation holder is Merck Sharp & Dohme B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU